AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Study to Describe Treatment Patterns and Outcomes in EGFRm NSCLC Patients in Belgium
Completed
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- Drug: 1L treatmentDrug: 2L TreatmentDrug: 3L treatment
- First Posted Date
- 2018-12-03
- Last Posted Date
- 2020-05-08
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 141
- Registration Number
- NCT03761901
- Locations
- 🇧🇪
Research Site, Yvoir, Belgium
An Active and Placebo-Controlled Study of Brazikumab in Participants With Moderately to Severely Active Crohn's Disease
Phase 2
Terminated
- Conditions
- Crohn's DiseaseIBD
- Interventions
- First Posted Date
- 2018-11-29
- Last Posted Date
- 2023-11-21
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 89
- Registration Number
- NCT03759288
- Locations
- 🇬🇧
Research Site, West Bromwich, United Kingdom
Efficacy and Safety of MEDI7352 in Subjects With Painful Diabetic Neuropathy
- First Posted Date
- 2018-11-28
- Last Posted Date
- 2023-09-07
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 112
- Registration Number
- NCT03755934
- Locations
- 🇬🇧
Research Site, Stockton-on-Tees, United Kingdom
Safety and Tolerability Study of AZD4831 in Patients With Heart Failure.
- First Posted Date
- 2018-11-28
- Last Posted Date
- 2021-07-19
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 41
- Registration Number
- NCT03756285
- Locations
- 🇸🇪
Research Site, Stockholm, Sweden
A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer
Phase 1
Active, not recruiting
- Conditions
- Triple Negative Breast Neoplasms
- Interventions
- First Posted Date
- 2018-11-15
- Last Posted Date
- 2025-01-27
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 243
- Registration Number
- NCT03742102
- Locations
- 🇬🇧
Research Site, Oxford, United Kingdom
A Study to Assess the Pulmonary Distribution of Budesonide, Glycopyrronium and Formoterol Fumarate
Phase 1
Completed
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- First Posted Date
- 2018-11-14
- Last Posted Date
- 2018-11-14
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 10
- Registration Number
- NCT03740373
- Locations
- 🇬🇧
Research Site, Pentrebach, United Kingdom
Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients
Phase 3
Active, not recruiting
- Conditions
- Advanced Ovarian Cancer
- Interventions
- Drug: Carboplatin+Paclitaxel
- First Posted Date
- 2018-11-09
- Last Posted Date
- 2025-01-29
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1407
- Registration Number
- NCT03737643
- Locations
- 🇹🇷
Research Site, Izmir, Turkey
A Phase I Study of MEDI9447 (Oleclumab) in Japanese Patients
Phase 1
Completed
- Conditions
- Advanced Solid Malignancies
- Interventions
- Drug: MEDI9447 (oleclumab)
- First Posted Date
- 2018-11-09
- Last Posted Date
- 2019-07-08
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 6
- Registration Number
- NCT03736473
- Locations
- 🇯🇵
Research Site, Chuo-ku, Japan
Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer
Phase 3
Active, not recruiting
- Conditions
- Metastatic Castration-resistant Prostate Cancer
- Interventions
- First Posted Date
- 2018-11-07
- Last Posted Date
- 2025-03-04
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 895
- Registration Number
- NCT03732820
- Locations
- 🇬🇧
Research Site, Swansea, United Kingdom
Durvalumab+ Gemcitabine/Cisplatin (Neoadjuvant Treatment) and Durvalumab (Adjuvant Treatment) in Patients With MIBC
Phase 3
Active, not recruiting
- Conditions
- Muscle Invasive Bladder Cancer
- Interventions
- First Posted Date
- 2018-11-06
- Last Posted Date
- 2025-02-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1063
- Registration Number
- NCT03732677
- Locations
- 🇻🇳
Research Site, Hochiminh, Vietnam
© Copyright 2025. All Rights Reserved by MedPath